Gynecology
International clinical evidence for hirudotherapy in pelvic inflammatory disease, endometriosis, and gynecological conditions
Gynecologic indications are investigational (Tier C). See How Evidence Is Graded for the tier framework and Coverage Map for an organ-system view.
Off-label use — not FDA-cleared for this indication
Cleared indication: Gynecological applications (parametritis, adnexitis, endometriosis, salpingo-oophoritis)
Off-label prescribing is legal in the United States and remains a clinical decision. The discussion below is provided for educational context and does not represent an FDA-cleared indication.
Investigational Application
International Clinical Evidence
Gynecological applications represent one of the most extensively documented hirudotherapy domains, with data spanning six decades (1944-2003) and over 700 patients across 18 investigations. The evidence includes two controlled trials (Gelman, 1962, n=155; Khardikov et al., 2003, n=50). No randomized controlled trials exist for any gynecological indication.
Biological Rationale
Inflammatory diseases of the female reproductive organs feature microvascular compromise within pelvic venous and lymphatic plexuses, peritoneal adhesion formation, and chronic tissue edema. Infection damages endothelial integrity, activates local coagulation, and impairs drainage, creating a self-perpetuating cycle of congestion, hypoxia, and fibrosis. Conditions such as endometriosis and tubal obstruction share overlapping vascular and fibrotic pathophysiology.
Anti-Inflammatory
Eglins and bdellins inhibit elastase, cathepsin G, trypsin, and plasmin, attenuating neutrophil-mediated tissue damage central to parametritis, adnexitis, and endometriosis.
Antimicrobial
Destabilase-L provides bactericidal lysozyme activity against gram-positive pathogens (S. aureus), relevant to puerperal infections, mastitis, and vaginal dysbiosis.
Decongestive
Hyaluronidase facilitates edema drainage and enhances tissue permeability, addressing lymphatic congestion that perpetuates chronic pelvic inflammation and adhesions.
Anticoagulant
Hirudin, calin, and saratin address the hypercoagulable microenvironment in pelvic inflammation, where microthrombosis contributes to tissue ischemia and fibrosis.
Analgesic
Kininases degrade bradykinin locally, providing analgesia particularly relevant to chronic pelvic pain and endometriosis-associated pain syndromes.
Anti-Adhesion
Hyaluronidase, proteinase inhibitors, and microcirculatory enhancement collectively target the adhesion cascade in tubal obstruction and endometriosis.
Clinical Evidence
Nineteen studies investigated gynecological hirudotherapy. All originate from Russian/Eastern European centers (1944-2003) except one French case report. The two controlled trials (Gelman, 1962; Khardikov et al., 2003) provide the strongest evidence.
GRADE Evidence Level: Low
Observational studies or RCTs with serious limitations
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Gelman 1962 | Controlled trial | Parametritis / adnexitis (n=155) | Protocol details in the clinician view | Sustained improvement at 12-18 mo | 76% vs 25% sustained improvement Largest controlled gynecological trial |
| Khardikov et al. 2003 | Controlled trial | Chronic salpingo-oophoritis (n=50) | Protocol details in the clinician view | Blood flow, inflammatory resolution | 80% vs 40% resolution (p<0.01) |
| Gromova 2000 | Case series | Acute/chronic salpingo-oophoritis (n=70) | Protocol details in the clinician view | Pain, well-being, functional capacity | Accelerated recovery at all stages |
| Zhivoglyad & Nikonov 1998 | Case series | Endometriosis (n=40) | Protocol details in the clinician view | Ultrasound assessment | 60% no residual endometriosis on US |
| Startseva et al. 2001 | Case series | Endometriosis (refractory) (n=41) | Protocol details in the clinician view | Pain, blood loss, fertility | Blood loss decreased in 37/41 patients (90%); 4 pregnancies |
| Kurgina 2000 | Case series | Bacterial vaginosis (n=28) | Protocol details in the clinician view | Clinical/microbiological cure | complete clinical response in all 28 patients; full lactobacillus restoration 11 monotherapy; 17 HT+metronidazole |
| Batoev 1999 | Case series | Hydrosalpinx (prior failure) (n=20) | Protocol details in the clinician view | US assessment | 80% undetectable; 20% decreased |
| Platonov 1998 | Comparative series | Postpartum wounds/cesarean (n=95) | Protocol details in the clinician view | Infiltrate resolution | Good response; improved microcirculation |
| Galchenko & Shkolny 1969 | Case series | Chronic adnexitis (n=25) | Protocol details in the clinician view | TEG, pain, mobility | TEG correction; increased mobility |
| Chaban et al. 1995 | Mixed case series | Gynecological diseases (n=73) | Protocol details in the clinician view | Clinical improvement | Effective; alternative to surgery for myomas |
Parametritis & Adnexitis — Detailed Findings
The most extensively documented indication, with five studies spanning 1944-1969. Parametritis begins with infection penetrating venous and lymphatic plexuses, progressing to parametrial tissue involvement and potential abscess formation.
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Salpingo-Oophoritis — Detailed Findings
Khardikov et al. (2003) studied chronic salpingo-oophoritis: HT group (n=20) vs controls (n=30). HT produced more pronounced pelvic blood flow improvement (p<0.01). Resolution: 80% HT vs 40% controls; significant regression in 20% vs 50%; 10% of controls showed no improvement.
Gromova (2000) observed 70 patients with acute/chronic disease. HT accelerated pain relief, well-being improvement, and functional capacity restoration. Recommended at four stages: infiltrative, subsiding acute, chronic, and during complications.
Endometriosis — Detailed Findings
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Bacterial Vaginosis & Hydrosalpinx
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Infertility, Postpartum & Other Indications
Infertility: In individual reports, previously infertile women conceived: Gromova (2000) 5/12; Startseva et al. (2001) 4 endometriosis patients; Kurgina (2000) 1/3. Results support biological plausibility through adhesion resolution and microcirculation improvement.
Postpartum: Three reports (Platonov 1998 alone: 95 treated women plus a 35-woman comparison group) described rapid infiltrate resolution, pain reduction, and reduced post-cesarean complications (Platonov 1998; Batoev 1999; Gazazyan & Khardikov 2003).
Mixed series: Chaban et al. (1995, n=73) concluded HT effective for gynecological diseases (both inflammatory and non-inflammatory) and a rational surgical alternative for myomas.
Clinical Protocol
Inflammatory Indications
- Parametritis / adnexitis — adjunct to antimicrobials
- Salpingo-oophoritis — adjunct to pharmacotherapy
- Postpartum endometritis, suture infiltrates, metrophlebitis
- Infected perineal tears / post-cesarean wounds
- Purulent mastitis — adjunct to antimicrobials
Non-Inflammatory Indications
- Bacterial vaginosis — monotherapy or adjunct
- Hydrosalpinx — monotherapy after conventional failure
- Endometriosis — pain, menstrual dysfunction, refractory
- Tubal / endocrine infertility — adjunct
- Uterine fibroids / myomas — adjunct or surgical alternative
Pre-Procedure
- Microbiological diagnosis (cultures, bacterioscopy, vaginal pH); initiate antimicrobials as indicated
- Baseline pelvic ultrasound for structural conditions
- Complete coagulation profile; review anticoagulant/antiplatelet medications
- CBC baseline for multi-session courses
- Rule out pregnancy and pelvic malignancy
Application Sites
Protocol details (number of leeches, application sites, session length and frequency, course) are shown in the clinician view. Clinicians: switch the audience selector in the top bar to “Clinician”.
Dosing Parameters
Post-Procedure
- Tamponade removal at 16 hours; monitor oozing (4 to 24 hours expected)
- Follow-up ultrasound at course completion for structural conditions
- Reassess pain, temperature, ESR, pelvic mobility every 2-3 sessions
- CBC at mid-course and completion (cumulative blood loss detection)
- Repeat cultures for bacterial vaginosis at course end
Safety Considerations
- Pelvioperitonitis (ABSOLUTE): Risk of sepsis generalization and DIC (Yakimova, 1999).
- Acute septic endometritis (ABSOLUTE): Same DIC/sepsis risk. Distinguish treatable infiltrative/subacute stages from contraindicated septic states.
- Active hemorrhage: SGS anticoagulant/antiplatelet properties exacerbate bleeding.
- Pregnancy: Relative contraindication.
- Suspected malignancy: Tissue diagnosis first; local application may enhance neoplasm blood flow.
Stage-Specific Risk
Indicated: Infiltrative stage (promotes resolution), subsiding acute (accelerates resolution), chronic course (addresses fibrosis and adhesions). Case-by-case: Complication stage (suppuration may respond; peritonitis contraindicated). Contraindicated: Acute septic phase and pelvioperitonitis (DIC/sepsis risk; Yakimova, 1999).
Drug Interactions
| Medication | Interaction | Action |
|---|---|---|
| Anticoagulants | Additive (hirudin, calin, saratin, apyrase) | Careful monitoring; dose adjustment |
| Antiplatelet agents | Additive platelet inhibition | Individual risk-benefit assessment |
| Antimicrobials | No adverse interactions | Continue as indicated |
| Hormonal therapy / OCP | Theoretical estrogen-thrombotic concern | Standard precautions |
Monitoring
- Coagulation: Baseline and periodic (especially endometriosis extended courses)
- CBC: Cumulative blood loss; critical for hyperpolymenorrhea patients
- Ultrasound: Baseline and course completion for structural conditions
- Clinical: Pain, temperature, ESR every 2-3 sessions
- Microbiology: Repeat cultures for vaginosis at course end
Evidence Gaps & Research Priorities
Despite hundreds of patients across six decades, the evidence has significant limitations: no RCTs, all data from Russian/Eastern European centers, variable outcome measures, and combined interventions limiting attribution.
- Chronic salpingo-oophoritis: RCT with pelvic Doppler and inflammatory markers
- Bacterial vaginosis: Controlled comparison with microbiome analysis
- Endometriosis pain: Pilot with VAS and EHP-30 endpoints
- Hydrosalpinx: Prospective cohort with serial US and hysterosalpingography
- Reproductive outcomes: Prospective fertility registry
Key Takeaways
Controlled trial data: Three-fold improvement in parametritis (76% vs 25% at 12-18 mo) and two-fold in salpingo-oophoritis (80% vs 40%, p<0.01) across two non-randomized controlled trials.
Microbiome restoration: complete clinical response in all 28 patients with full lactobacillus restoration in bacterial vaginosis (n=28), suggesting dysbiosis correction rather than pathogen suppression.
Critical contraindications: Pelvioperitonitis and acute septic endometritis are absolute contraindications (DIC/sepsis risk). Stage-appropriate patient selection is fundamental.
Investigational status: All gynecological applications are off-label in the US. Evidence is Level III-IV from Russian/Eastern European centers. RCTs needed.
References
- Batoev, D. B. (1999). Hirudotherapy for purulent-septic complications in the postpartum period. Proc. 6th Sci.-Pract. Conf. Assoc. Hirudologists of Russia and CIS Countries, Pyatigorsk, 1999, pp. 57-8.
- Batoev, D. B. (1999a). Treatment of hydrosalpinx at the Ulan-Ude Gynecological Hospital (n=20). Proc. 6th Sci.-Pract. Conf. Assoc. Hirudologists of Russia and CIS Countries, Pyatigorsk, 1999, p. 56.
- Bornshtein, S. A. (1952). Leeches for acute inflammatory diseases of the female genitals.
- Chaban, T. N., Kapralova, V. V., & Savinov, V. A. (1995). Hirudotherapy in gynecological practice. In: Proceedings of the 4th Conference of the Association of Hirudologists (ed. V. V. Ptushkin). Moscow, p. 24.
- Galchenko, V. K., & Shkolny, V. K. (1969). Changes in thromboelastogram parameters during hirudotherapy for chronic adnexitis.
- Gazazyan, M. G., & Khardikov, A. V. (2003). HT after cesarean section.
- Gelman, Ya. M. (1962). Comparative study in parametritis/adnexitis (n=155).
- Gromova, N. N. (2000). HT in salpingo-oophoritis and infertility (n=70).
- Khardikov, A. V., et al. (2003). Controlled study, chronic salpingo-oophoritis (n=50).
- Kurgina, M. K. (2000). HT for bacterial vaginosis (n=28).
- Lukyanova, N. V. (1999). HT for tubo-peritoneal infertility.
- Platonov, E. A. (1998). HT in the treatment of postpartum pyoseptic disorders (n=95).
- Shamileva, A. E., & Kulanin, A. N. (2001). Sanatorium gynecological HT (Mashuk Sanatorium, Pyatigorsk).
- Shpolyansky, G. M. (1944). HT in parametritis (n=15).
- Shvets, T. I. (1967). On hirudotherapy in inflammatory conditions of the female reproductive organs.
- Startseva, N. V., et al. (2001). HT for endometriosis (n=41).
- Yakimova (1999), cited in Baskova, I. P., & Isakhanyan, G. S. (2004). Hirudotherapy: Science and Practice. Moscow: Monolit.
- Zhivoglyad, R. N., & Nikonov, G. I. (1998). HT for endometriosis (n=40).
Related Resources
Clinical Specialties
All 14 medical specialties reviewed.
Endocrinology
Overlapping climacteric and metabolic applications.
Surgery
Postoperative and wound healing applications.
Proteinase Inhibitors
Eglins, bdellins, LDTI — anti-inflammatory compounds.
All Indications
Complete indication list with evidence tiers.